Response to Apalutamide Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN by DECIPHER Genomic Classifier Score

Posted by Fred Saad, MD, FRCS | Nov 2019

Fred Saad, MD, FRCS, presented “Response to Apalutamide Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN by DECIPHER Genomic Classifier Score” for the Grand Rounds in Urology audience in November 2019.

How to cite: Saad, Fred. “Response to Apalutamide Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN by DECIPHER Genomic Classifier Score” November, 2019. Accessed Apr 2024. https://grandroundsinurology.com/response-to-apalutamide-among-patients-with-nmcrpc-from-spartan-by-decipher-genomic-classifier-score/

Response to Apalutamide Among Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN by DECIPHER Genomic Classifier Score -Summary:

Fred Saad, MD, FRCS, presents findings from an exploratory analysis he led and presented at the American Urological Association’s 2019 Annual Meeting. The study evaluated the association between DECIPHER genomic classifier (GC) score and metastasis-free survival following apalutamide treatment in nonmetastatic castrate-resistant prostate cancer (nmCRPC) patients included in the SPARTAN study.

About The Author

Fred Saad, MD, FRCS

Fred Saad, MD, FRCS, is Professor and Chairman of Urology and Director of Genitourinary Oncology at the University of Montreal Hospital Center (CHUM). He holds the Raymond Garneau Chair in Prostate Cancer Research and is the Director of Clinical Research and the Molecular Oncology Research Laboratory in Prostate Cancer. He is a past President of the Canadian Urologic Association and was Chair of the NCIC GU Group and CUOG. Dr. Saad has played a leadership role and been a co-author on many of the practice-changing clinical trials and publications in advanced prostate cancer over the last 20 years. He presently sits on 7 steering committees of ongoing international clinical trials and serves on several guideline committees. He is a member of several editorial boards, including Lancet Oncology, JAMA Oncology, Nature Reviews Urology, Genitourinary Cancer, and Urology. He has published over 500 peer-reviewed articles, 50 book chapters, and 8 books, including Understanding Prostate Cancer, which is designed for patients and has sold over 250,000 copies to date. With an h-factor of 108 and over 50,000 citations, he is listed as one of the world’s most cited clinician-scientists. Dr. Saad’s research interests include novel therapeutics in prostate cancer, molecular prognostic markers, and mechanisms of progression. He has over 40 ongoing clinical and basic research projects and has received over $30 million in research grants. His numerous awards include the lifetime achievement award from the CHUM Research Center and the Lifetime Achievement Award from the Quebec Urologic Association. In 2018, Dr. Saad was named a Knight of The National Order of Quebec, the highest honor given by the Quebec government.

Join the GRU Community

- Why Join? -

Share This

Chat with usLiveChat